

HIV Regimen Ordering Charts:
Table 1. Combination Antiretrovirals

Name	Drug Components	Formulary Status	Inpatient Order Recommendation
Atripla	600mg Efavirenz, 200mg Emtricitabine, 300 mg TDF	Formulary	Order Home Regimen
Biktarvy	50mg Bictegravir, 200mg Emtricitabine, and 25mg TAF	Formulary	Order Home Regimen
Cabenuva	600mg Cabotegravir, 900mg Rilpivirine	Non-Formulary	Confirm time of last administration; if >30 days, consult ID
Cimduo	300mg TDF + 300mg Lamivudine	Non-Formulary	TDF + Lamivudine once daily
Combivir	150mg Lamivudine, 300mg Zidovudine	Formulary	Order Home Regimen
Complera	200mg Emtricitabine, 25mg Rilpivirine, 300mg TDF	Non-Formulary	Truvada + Rilpivirine once daily
Delstrigo	100mg Doravirine, 300mg Lamivudine, 300mg TDF	Non-Formulary	Doravirine + Truvada once daily ¹
Descovy	200mg Emtricitabine, 25mg TAF	Formulary	Order Home Regimen
Dovato	50mg Dolutegravir, 300mg Lamivudine	Non-Formulary	Dolutegravir + Lamivudine once daily
Epzicom	600mg Abacavir, 300mg Lamivudine	Formulary	Order Home Regimen
Evotaz	300mg Atazanavir, 150mg Cobicistat	Non-Formulary	Atazanavir + 100mg Ritonavir once daily ²
Genvoya	150mg Elvitegravir, 150mg Cobicistat, 200mg Emtricitabine, 10mg TAF	Formulary	Order Home Regimen
Juluca	50mg Dolutegravir, 25mg Rilpivirine	Non-Formulary	Dolutegravir + Rilpivirine once daily
Kaletra	200mg Lopinavir, 50mg Ritonavir	Formulary	Order Home Regimen
Odefsey	200mg Emtricitabine, 25mg Rilpivirine, 25mg TAF	Non-Formulary	Descovy + Rilpivirine once daily
Prezcobix	800mg Darunavir, 150mg Cobicistat	Formulary	Order Home Regimen
Stribild	150mg Elvitegravir, 150mg Cobicistat, 200mg Emtricitabine, 300mg TDF	Formulary	Order Home Regimen
Symfi	600mg Efavirenz, 300mg lamivudine, 300mg TDF	Non-Formulary	Atripla once daily ¹
Symtuza	800mg Darunavir, 150mg Cobicistat, 200mg Emtricitabine, 10mg TAF	Non-Formulary	Descovy + Prezcobix once daily ³
Triumeq	600mg Abacavir, 300mg Lamivudine, 50mg Dolutegravir	Formulary	Order Home Regimen
Truvada	200mg Emtricitabine, 300mg TDF	Formulary	Order Home Regimen

TAF= Tenofovir Alafenamide Fumarate

TDF= Tenofovir Disoproxil Fumarate

Table 2. Single Drug Components - Non-Formulary

Prior to Admission Regimen	Drug Component	Formulary Status	Inpatient Order Recommendation
Fuzeon	Enfuvirtide	Non-Formulary	Consult ID
Rukobia	Fostemsavir	Non-Formulary	Consult ID
Selzentry	Maraviroc	Non-Formulary	Consult ID
Sunlenca	Lenacapavir	Non-Formulary	Consult ID
Trogarzo	Ibalizumab	Non-Formulary	Consult ID
Tyboost	Cobicistat	Non-Formulary	Ritonavir 100 mg once daily ¹
Vocabria	Cabotegravir	Non-Formulary	Consult ID

Table 3. Single Drug Components – Formulary

Prior to Admission Regimen	Drug Component	Formulary Status	Inpatient Order Recommendation
Edurant	Rilpivirine	Formulary	Order Home Regimen
Emtriva	Emtricitabine	Formulary	Order Home Regimen
Epivir	Lamivudine	Formulary	Order Home Regimen
Intelence	Etravirine	Formulary	Order Home Regimen
Isentress	Raltegravir	Formulary	Order Home Regimen
Norvir	Ritonavir	Formulary	Order Home Regimen
Pifeltro	Doravirine	Formulary	Order Home Regimen
Prezista	Darunavir	Formulary	Order Home Regimen
Reyataz	Atazanavir	Formulary	Order Home Regimen
Sustiva	Efavirenz	Formulary	Order Home Regimen
Tivicay	Dolutegravir	Formulary	Order Home Regimen
Vemlidy	TAF	Formulary	Order Home Regimen
Viramune	Nevirapine	Formulary	Order Home Regimen
Viread	TDF	Formulary	Order Home Regimen
Ziagen	Abacavir	Formulary	Order Home Regimen

TAF= Tenofovir Alafenamide Fumarate

TDF= Tenofovir Disoproxil Fumarate

References

1. Guidelines Working Groups of the NIH Office of AIDS Research Advisory Council. Guidance for Non-HIV-Specialized Providers Caring for Persons with HIV Who Have Been Displaced by Disasters (such as a Hurricane). Department of Health and Human Services. Year. Available at <https://clinicalinfo.hiv.gov/en/guidelines/guidelines-caring-persons-hiv-disaster-areas/guidance-non-hiv-specialized-providers>. Appendix C: Accessed (8/21/2023)
2. Marin R-C, Behl T, Negrut N, Bungau S. Management of Antiretroviral Therapy with Boosted Protease Inhibitors—Darunavir/Ritonavir or Darunavir/Cobicistat. *Biomedicines*. 2021; 9(3):313. <https://doi.org/10.3390/biomedicines9030313>
3. Common Drug Review New Combination Product Submission: Darunavir/Cobicistat/Emtricitabine/Tenofovir alafenamide (Symtuza): (Janssen Canada Inc.): Indication: A complete regimen for the treatment of HIV type 1 infection in adults and adolescents (aged 12 years and older with body weight at least 40 kg) with no known mutations associated with resistance to the individual components of Symtuza [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2018 Aug. 4, Discussion. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK540532/>